Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
23 January 2019 | Story Charlene Stanley | Photo Charlene Stanley
Michele Middle
Michelle Middle, CMO of Farmovs, looks forward to expanding their operations after the UFS acquired 100% shareholding in 2018.

In medical research, there are NO shortcuts.

The journey of a new medicine from lab to pharmacy shelf takes on average at least 10 years.

Michelle Middle’s journey from young medical graduate starting her first job at FARMOVS to becoming the company’s Chief Medical Officer, was more than twice that long. It was a journey that systematically and adequately equipped her to now Co-captain this flagship enterprise through its biggest challenge yet.

Michelle remembers how Farmovs started in 1974 as a research centre in the Department of Pharmacology. After graduating as medical doctor, she joined Farmovs in 1993, shortly before they moved to their current extensive facilities just south of the Sasol Library.

In 2000, international Clinical Research Organization (CRO) giant Parexel acquired a 70% shareholding, and the name changed to Farmovs-Parexel.

“Parexel really invested a lot in infrastructure and technology, bringing facilities here on par with the best in the world,” says Michelle.

Her own journey in medical research took her to George and later to the US and UK, where she held various international executive leadership positions in international companies.

When the UFS acquired a 100% shareholding in Farmovs earlier this year, she came full circle, as she returned to Bloemfontein to spearhead the expansion of patient studies in collaboration with the Faculty of Health Sciences.

“The opportunities we have here are really enormous,” says an excited Michelle.

“We are the only university in the country with this kind of infrastructure. Apart from our state-of-the-art bioanalytical lab, we also have facilities to accommodate close to 100 research participants. We now have 45 years’ experience in advanced medical research, plus established international clients. We can provide pharmaceutical companies with basically everything they need to develop new medicines.”

Another exciting development is that they are expanding their clinical-trial patient population next year from healthy individuals to people suffering from a host of chronic conditions.

“While they are part of our clinical trials, patients gain valuable insight in their own conditions. We also sometimes pick up underlying medical issues they were not even aware of,” says Michelle.

The 150 Farmovs staff members range from doctors and nurses, to technologists, medical writers, and managers. While not technically part of the university staff, they form a valued part of the Bloemfontein Campus community.

News Archive

UFS academic discusses Dutch, Afrikaans and African languages
2006-05-22

During the colloquium presented in Belgium by the Province Antwerp were from the left Prof Pol Cuvelier (University of Antwerp), Prof Theo du Plessis (Director: Unit for Language Management at the UFS), Mr Ludo Helsen (Permanent Deputy: Province of Antwerp) and Mr Jean-Pierre Rondas (Flemish radio journalist).

________________________________________________

UFS academic discusses Dutch, Afrikaans and African languages at international conference

Prof Theo du Plessis, Director of the Unit for Language Management at the University of the Free State (UFS), was the main speaker at a colloquium titled “Routes:  Where to now? - Een traject van het Nederlands naar het Afrikaans en de Afrikatalen”, which was recently presented by the Province Antwerp in Belgium.

 The aim of the colloquium was to discuss the future cooperation in the field of language between the Province Antwerp and South Africa. 

 The Province Antwerp is already involved with projects in South Africa.  One of these projects is the Multilingual Information Development Programme (MIDP), a partnership project between the UFS and the Free State Province that is mainly funded by the Province Antwerp. 

 The project has been running since 1999 and was recently in the news with the presentation of a symposium on multilingualism and exclusion on the Main Campus of the UFS.  It is hoped that the Routes colloquium will indicate new stages on which can be added to the already successful cooperation in the area of language.

 Prof Du Plessis’s presentation titled “Nederlands, Afrikaans en die Afrikatale – kan samewerking slaag? Die geval MIDP in die Vrystaat”, investigated the successes that have been made with the MIDP.  He discussed two possible approaches to cooperation in the areas of language, that of a sentimentalistic  approach against an instrumentalistic approach. 

Cooperation in the first approach makes language the aim.  In the second approach language is used as a means to a greater aim.  According to Prof du Plessis the first approach is driven by a romantisised idea about the relation between the Flemish and Afrikaans speaking people, which may unfortunately polarise the position of Afrikaans in South Africa even further.

 He argues that, given the time that we are in, the second approach will deliver more constructive results as language can among others be used for to further  democracy in South Africa.   This can happen by cooperation in the institutionalising of multilingualism in our society.  The more languages are used in education, law and government administration, the more we can be assured a successful democracy.

 The Routes colloquium was facilitated by the well-known Flemish radio journalist, Jean-Pierre Rondas. About twenty South African and Flemish language specialists took part in the colloquium.  Dr Fritz Kok, outgoing chief executive officer of the ATKV took part in the opening ceremony and Dr Neville Alexander from the University of Cape Town and well-known activist for multilingualism in South Africa was also one of the main speakers.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept